%20(2).png)
Prof Mark Mamula (Yale School of Medicine) joined us for a webinar, during which he shared updates about the EGFR/HER2 Canine Cancer Vaccine study.
Watch the full video here:
Highlights:
Mavis's story -
Mavis joined the Wag Love Life event in 2023, shortly after being diagnosed with osteosarcoma. After learning about the EGFR/HER2 vaccine trial, she received radiation therapy treatment together with the vaccine. She is now a 12+ month osteosarcoma survivor and continues to receive monthly chemo and bisphosphonates.
Mavis and her mom returned to the Wag Love Life walk a year later, in May 2024, walking on her four legs!
Ranger's Story
Rick Kneisel shared his and Ranger's experiences. Ranger received the vaccine after lung metastasis was found. The lung metastasis disappeared, and he lived for 3+ years.
Prof Mamula's Talk
Canine cancers are virtually identical to human cancers, with similar growth, metastasis, and how they cause morbidity and mortality.
EGFR/HER2 vaccine may help patients with many different cancer types, but the current clinical trial is enrolling dogs with Osteosarcoma, Hemangiosarcoma, and Transitional Cell Carcinoma.
The Canine Cancer Alliance page here has the locations of clinical trial sites and other information. A new Connecticut location was recently added.
Therajan LLC is commercializing the vaccine; additional information can be found on their website.
Based on their data, all dogs who received the vaccine had an immune response, but some had weaker responses while some had stronger. However, it is noted that some dogs may have had weak immune responses but had great clinical responses and outcomes and lived much longer. This is also true conversely. So don't worry about your dog's antibody response after vaccination.
Hunter a FEMA rescue dog received vaccination before amputation surgery and conventional treatment. And is now a 2+ year osteosarcoma survivor.
Checkpoint Inhibitor Cancer Therapy is another type of immunotherapy that is emerging to help dogs. Merck released the first PD1 checkpoint inhibitor for dog cancer called Gilvetmab. A new combination immunotherapy study is being launched to see if it will improve responses compared to either of the therapies given individually.
Check out other articles and videos
Questions? Email us at info@ccralliance, and we'll get back to you as soon as we can!
Canine Cancer Alliance is a non-profit organization supporting research for canine cancer cures.
All information the Canine Cancer Alliance website provides is for informational purposes only. It is not intended to be a substitute for professional veterinary advice.
Always seek guidance from your veterinarian with any questions regarding your pet’s health and medical condition.